FLASH THERAPEUTICS
Toulouse / 3 Avenue Hubert Curien
|
Based on its proprietary LentiFlash® technology and Vectalys manufacturing platform, the company has potential to enable and advance the development of treatments mediated by RNA and DNA delivery for a broad range of diseases, including cancer, infectious disease and genetic diseases. |
|||||||||
| Axe métier : |
Médicament
|
||||||||
| Catégorie : | PME | ||||||||
| Forme juridique : | SAS | ||||||||
| Site web : | https://www.flashtherapeutics.com/ | ||||||||
| Chiffre d'affaire : |
3,283,067.00 K€ |
||||||||
Contact : |
|||||||||
ICHE AlexandraGene Engineering Project Manager |
|||||||||
| Email : | alexandra.iche@flashtherapeutics.com | ||||||||
LAMOUROUX LucilleGene Engineering Manager |
|||||||||
| Email : | lucille.lamouroux@vectalys.com | ||||||||
BOUILLE PascaleCEO |
|||||||||
| Email : | pascale.bouille@flashtherapeutics.com | ||||||||
DUTHOIT Christinechef de projet ingénierie cellulaire et immunologie |
|||||||||
| Email : | christine.duthoit@flashtherapeutics.com | ||||||||
DARRIGAN SandyContrats & Intellectual Property Manager |
|||||||||
| Email : | sandy.darrigan@flashtherapeutics.com | ||||||||